Studies leading to the identification of ZD1839 (Iressa (TM)): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitortargeted to the treatment of cancer

Authors
Barker, AJ Gibson, KH Grundy, W Godfrey, AA Barlow, JJ Healy, MP Woodburn, JR Ashton, SE Curry, BJ Scarlett, L Henthorn, L Richards, L
Citation
Aj. Barker et al., Studies leading to the identification of ZD1839 (Iressa (TM)): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitortargeted to the treatment of cancer, BIOORG MED, 11(14), 2001, pp. 1911-1914
Citations number
10
Categorie Soggetti
Chemistry & Analysis
Journal title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
ISSN journal
0960894X → ACNP
Volume
11
Issue
14
Year of publication
2001
Pages
1911 - 1914
Database
ISI
SICI code
0960-894X(20010723)11:14<1911:SLTTIO>2.0.ZU;2-T
Abstract
This paper describes the development of the epidermal growth factor recepto r tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoli ne compounds. ZD1839 has suitable properties for use as a clinically effect ive drug and shows activity against human tumours. In particular, the use o f pharmacokinetic data in the development of ZD1839 is discussed. (C) 2001 Elsevier Science Ltd. All rights reserved.